Details of Disease

General Information of Disease (ID: DISZ919E)

• Disease Name: Nerve injury
• Disease Class: ND56: Unspecific body region injury
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISZ919E: Nerve injury
• ICD Code:
  ICD-11: ICD-11: ND56.4
  ICD-10: ICD-10: T14.4
  Expand ICD-11: 'ND56.4
  Expand ICD-10: 'T14.4

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Lexipafant	DMZ2YBE	Phase 2	Small molecular drug	[1]
NS-7	DM3H82Q	Phase 2	Small molecular drug	[2]
Triapine	DM7XZY5	Phase 2	Small molecular drug	[3]
ATI-355	DMBKO2W	Phase 1	Antibody	[4]
PACAP38	DMX9AK6	Phase 1	NA	[5]
UK-240455	DMSCXB7	Phase 1	Small molecular drug	[6]

This Disease is Treated as An Indication in 8 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BMS-204352	DMFZNLH	Discontinued in Phase 3	Small molecular drug	[7]
Furnidipine	DME94QF	Discontinued in Phase 3	Small molecular drug	[8]
EPC-K1	DMZKBU9	Discontinued in Phase 2	Small molecular drug	[9]
Gavestinel	DM8IL1U	Discontinued in Phase 2	Small molecular drug	[10]
Lifarizine	DM3R8TI	Discontinued in Phase 2	Small molecular drug	[11]
CEREBROCRAST	DMK93VQ	Discontinued in Phase 1	Small molecular drug	[12]
SB-234551	DMX7PNY	Discontinued in Phase 1	Small molecular drug	[13]
BN-50726	DMTKJDS	Terminated	Small molecular drug	[14]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg. 1995 Oct;82(10):1414-20.
• [2] Preferential inhibition by a novel Na(+)/Ca(2+) channel blocker NS-7 of severe to mild hypoxic injury in rat cerebrocortical slices: A possible involvement of a highly voltage-dependent blockade of Ca(2+) channel. J Pharmacol Exp Ther. 2000 May;293(2):522-9.
• [3] PAN-811 inhibits oxidative stress-induced cell death of human Alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species. J Alzheimers Dis. 2009;17(3):611-9.
• [4] ClinicalTrials.gov (NCT00406016) Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI. U.S. National Institutes of Health.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2258).
• [6] UK-315716/UK-240455. Pfizer. Curr Opin Investig Drugs. 2001 Dec;2(12):1737-9.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2307).
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002558)
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007770)
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007924)
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003892)
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006562)
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1000).
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001821)